Development of new incretin drugs: Promising therapies

K. Kaur, C.S. Gautam

ABSTRACT

New agents are being added to the armamentarium of drugs used for the treatment of diabetes mellitus. Today, extensive research is being conducted on incretin hormones. Important among them are, Glucagon like peptide-1 (GLP-1) and Glucose dependent insulino tropic peptide (GIP). The gastrointestinal tract secretes these hormones in response to the ingestion of nutrients. These hormones increase secretion of insulin, decrease secretion of glucagon, decrease gastric emptying time (only by GLP-1). In addition, they decrease body weight and prevent development of resistance to insulin. They are rapidly degraded by dipeptidyl peptidase (DPP-IV) enzyme. Analogs of GLP-1 and GIP and inhibitors of DPP-IV are being synthesised. Exenatide, a synthetic analog of GLP-1, has recently been approved by the FDA, USA for use in patients with type 2 diabetes who have sub optimal control despite treatment with metformin and / or a sulphonylurea. Other GLP-1 analogs under clinical trial are: NN2211, CJ/C1131, and Albugon. No analog of GIP and inhibitor of DPP-IV have been approved by the FDA for clinical use till now. Vildagliptin, an inhibitor of DPP-IV, is under phase 2 clinical trials. The incidence of hypoglycemia is less with these incretin mimetics and inhibitors of DPP-IV. Minimal gastrointestinal side effects are seen. Analogs of GLP-1 have to be given subcutaneously, while inhibitors of DPP-IV can be given orally. There is a need to synthesise long acting analogs of GLP-1 and selective inhibitors of DPP-IV.

KEY WORDS: Diabetes mellitus, GLP-1, GIP, DPP-IV.
in the duodenum and the proximal part of the jejunum secrete it. The main stimulant for secretion of GIP is ingestion of meals rich in carbohydrates and lipid. Following ingestion, circulating plasma levels of GIP increase 10–20 fold. Secretion of GIP reaches peak concentration within 15–30 min of ingestion of oral glucose or lipids, even before the nutrients are absorbed into the gut. This suggests a potential role of other influences in secretion of GIP. The half-life of intact GIP is approximately 7 and 5 min in non-diabetic and diabetic persons, respectively.

Following secretion into the circulation, intact GIP (1–42 amide) is cleaved at the amino terminus by DPP-IV, resulting in the formation of the inactive truncated GIP (3–42 amide). This lacks incretin activity and may even act as an antagonist of GIP at its receptor.

**Action of GIP**

Initially, it was thought that GIP inhibits secretion of gastric acid. Therefore, it was named ‘gastric inhibitory peptide’. However, studies on humans have failed to demonstrate any significant role of physiologic GIP on secretion of gastric acid.

The incretin effect of GIP was first appreciated in the 1970s. The physiologic effects of GIP have been elucidated using receptor antagonists of GIP, peptide antagonists of GIP, and receptor knockout mice of GIP. Blocking the binding of GIP to its receptor leads to an attenuated glucose dependent secretion of insulin. This is in response to the loading of oral glucose in rats and mice used in experiments.

Administration of antagonists of GIP markedly reduces the postprandial release of insulin in rats. Ehali and colleagues demonstrated that infusion of GIP results in secretion of insulin only in the presence of elevated concentration of glucose. It was also demonstrated that GIP is not glucagonotropic in healthy humans in euglycemic and hyperglycemic conditions. The effect of endogenously released GIP appears to be an important mechanism of postprandial secretion of insulin and does not appear to play a role during fasting.

GIP stimulates proliferation of beta cell and survival of cells in INS-1 islet cell-line studies. In patients with type 2 diabetes, secretion of GIP is preserved, compared with individuals without diabetes. Infusion of GIP exhibits a marked reduction of insulinotropic activity in patients with type 2 diabetes. In other words, these patients, there is a decreased response of insulin secretion to the infusion of GIP, compared with non-diabetic control subjects. The GIP defect in insulin secretion is most pronounced in the late phase of secretion of insulin.

GIP plays a role in the metabolism of lipid by stimulating the activity of lipoprotein lipase, inducing the incorporation of fatty acids into adipose tissue, and stimulating the synthesis of fatty acid. The role of GIP in obesity is also being studied. It has been observed that GIP receptor knock out mice are protected from obesity induced by high fat diet. However, elimination of the effect of endogenous GIP may impair the postprandial secretion of insulin and, therefore, severely disturb glucose homeostasis.

**Glucagon like peptide-1**

GLP-1, a product of the glucagon gene was first identified in the early 1980s. GLP-1 is a 30/31 amino acid peptide. It is derived from a larger proglucagon precursor, which also releases other peptides like glucagon, GLP-2, oxyntomodulin, and glicentin. Like GIP, the GLP-1 receptors are widely expressed in pancreatic islets, brain, heart, kidney, and gastrointestinal tract. Enteroneurone L-cells are located predominantly in the ileum, and the colon secrete them.

Biologically active GLP-1 is of two major types, GLP-1 [7-37] and GLP-1 [7-36] amide, which differ by a single amino acid. The majority of the circulating GLP-1 is GLP-1 [7-36] amide. Both GLP-1 [7-37] and GLP-1 [7-36] amides are equipotent and have similar activities. Secretion of GLP-1 is controlled by both neural and endocrine cells. It is caused by entry of nutrients in the proximal GIP as well as by the subsequent direct contact of open type-L cells with nutrients that have been digested. Plasma levels of GLP-1 increase rapidly within minutes of ingestion and are highly correlated with the release of insulin. DPP-IV rapidly cleaves GLP-1 to its truncated inactive metabolite. These peptides have a short half-life of 2 min in both non-diabetic and diabetic patients. Like GIP, GLP-1 enhances secretion of insulin only in the presence of elevated concentration of glucose.

**Action of GLP-1**

Most of the actions of GLP-1 observed in animals have also been demonstrated in human studies. GLP-1 is responsible for a significant part of the response of insulin to oral glucose. It is not only an insulinotropic hormone, but also inhibits secretion of glucagon in a glucose dependent manner. Suppression of glucagon does not occur at hypoglycemic concentrations of plasma glucose, but requires the presence of euglycemia or hyperglycemia. GLP-1 leads to expansion of the mass of β cell via islet cell neogenesis. GLP-1 has also been shown that GLP-1 can induce the differentiation of two pancreatic ductile cell lines, ARIP (in rats) and PANG-1 (in humans) into insulin producing and insulin secreting cells. It has been seen that improvement in tolerance to glucose by GLP-1 is maintained for a long time. This suggests that these effects cannot be simply explained as caused by the modulation of preformed insulin secretion, but must involve more substantial modifications in the functional activity of β cells. It has been observed that GLP-1 drastically reduces the β cell apoptosis. Farilla et al observed that improvement in the viability of cell can cause a significant amelioration of the function of islet cell. In rodents, acute intracerebro-ventricular injection of GLP-1 or receptor agonists of GLP-1 results in reduction of food intake. Some studies have shown that peripheral administration as well as chronic intracerebro-ventricular administration of GLP-1 receptor agonist result in weight loss. Such results have been observed in some, but not all human studies. This reduction of food intake may be due to reduced gastric emptying rate. In a prospective, placebo controlled study by Zander et al, 20 patients with type 2 diabetes received GLP-1 or saline by continuous subcutaneous infusion for 6 weeks. Patients receiving GLP-1 had significant reduction in weight by 1.9 kg, inhibition of gastric emptying, and reduction in appetite.

In contrast to GIP, these effects are comparable in diabetics and non-diabetics.
Agonists of GLP-1 have neural actions. They act on the brain receptors of GLP-1. In addition to the circulating GLP-1, which enters the brain in the periventricular areas, GLP-1 is also synthesised in the nucleus solitarius of the brain stem.\(^{(47)}\) CNS effects of GLP-1 include regulation of food intake and body weight. GLP-1 is also a mediator of multiple stress responses. When infused into the lateral ventricle, it potentiates the release of corticortropin releasing hormone. It exhibits antiapoptotic and neurotrophic effects in neural cells, similar to its trophic actions in B cells. The effects of GLP-1 are similar to those of nerve growth factor. GLP-1 and receptor agonists of GLP-1 have shown protective effects that are dependent on concentration, with decreased amyloid ß protein 1–40 levels. This suggests a role for GLP-1 and its agonists in the treatment of Alzheimer’s disease.\(^{(17)}\)

In contrast to GIP, GLP-1 levels were shown to be reduced in obese patients with type 2 diabetes, who were resistant to insulin. This particularly occurred during the second hour after the nutrient stimulus.\(^{(22)}\) Infusion studies with GLP-1 in subjects with type 2 diabetes show a pronounced and preserved glucose dependent response of insulin to exogenously administered GLP-1.\(^{(48)}\) Together, the two hormones appear to act in an additive manner. Therefore, when GIP and GLP-1 infusions (that separately provide similar responses of insulin) were combined, the resulting response amounted to approximately the sum of the individual responses.\(^{(48)}\) Recently, mice with a double knockout of the GIP and GLP-1 receptors have been generated.\(^{(208, 251)}\) The results obtained in these animals are consistent with the additive effect of the two hormones on tolerance to glucose. The double knockout animals did not develop fastiging hyperglycemia in any of the studies, and their sensitivity to insulin was normal. Interestingly, the potent receptor agonist of GLP-1, exendin-4, which in control animals profoundly lowered blood glucose, had no effect in the double knockouts, suggesting that it acts exclusively via incretin receptors. Furthermore, valine pyrrolidide and SYR 106124 (inhibitors of DPP-IV), which lower blood glucose and improve tolerance to glucose in both GLP-1 and GIP single receptor knockout mice, had no effects in the double knockouts. This suggests that the effects of these inhibitors are exerted mainly by enhancing survival of GIP and GLP-1, without important involvement of other substrates.\(^{(52)}\)

**Current status of drugs under development**

Today, there are two approaches for utilising the antihyperglycemic potential of incretin hormones. They involve the use of incretin mimetics and inhibitors of DPP-IV, respectively.

**Incretin mimetics**

Incretins enhance insulin secretion that is glucose dependent and exhibit other antihyperglycemic actions following their release into circulation from the gut, in response to intake of food.

**Analog of GIP**

GIP has insulinotropic action. It stimulates ß cell proliferation and inhibits apoptosis in islet cell lines.\(^{(10, 23)}\) However, there are certain limitations in using GIP as a therapeutic agent. GIP has a short half life in the circulation due to rapid cleavage and degradation by enzyme DPP-IV.\(^{(53)}\) The cleaved metabolite is not only inactive, but may also function as a receptor antagonist of GIP.\(^{(31)}\)

The response to GIP infusion in subjects with type 2 diabetes is controversial. According to some studies, exogenous administration of GIP is comparatively less insulinotropic in obese, diabetic rodents.\(^{(53, 234)}\) Some other studies on animals have shown the insulinotropic and glucose lowering properties in both normal and diabetic rodents.\(^{(234, 246)}\) A trial on humans with type 2 diabetes has shown that stimulation of secretion of insulin by GIP is stronger after its bolus administration than during continuous infusion. According to this trial, the relative sensitivity of secretion of insulin to a bolus administration of GIP is almost preserved.\(^{(57)}\)

Several analogs of GIP modified at the Tyr-1 position, with resistance to degradation by DPP-IV, have been developed.\(^{(28)}\) Another novel, N-terminally protected, fatty acid derivatised analog of GIP, N-AcGIP (LysPAl(37)), has been studied in obese, diabetic (ob/ob) mice. Once daily injections of N-AcGIP (LysPal (37)) in ob/ob mice over a 14-day period significantly decreased plasma glucose and glycated hemoglobin and improved tolerance to glucose, compared with saline or native administration of GIP. Plasma insulin and pancreatic insulin content were significantly increased by N-AcGIP[LysPal(37)].\(^{(28)}\) Therapeutic strategies based on either augmenting or antagonizing GIP action are far from being established as the future therapy for Type 2 diabetes or obesity.

**Analogs of GLP-1**

The second incretin hormone, GLP-1, has already been exploited as a target drug. Several studies with infusion of GLP-1 in patients with type 2 diabetes have consistently shown improvements in glucose dependent secretion of insulin, reduction of glucose level, postprandial reduction of ghrelin, and improvements in ß cell function as well as gastric emptying. Although single or repeated subcutaneous injections of native GLP-1 decrease blood glucose in humans, this effect is transient and lasts for 1-2 h after injection of peptide.\(^{(30)}\) Maximum benefit can be achieved only if the response of incretin is for a longer period.

Exendin-4 is a naturally occurring 39-amino acid receptor agonist of GLP-1, isolated from the salivary gland venom of the lizard, Heloderma suspectum.\(^{(30)}\) Exendin-4 exhibits 53% amino acid identity to mammalian GLP-1 and binds to and activates receptor of GLP-1. Exendin-4 is highly resistant to the proteolytic activity of DPP-IV and exhibits a longer duration of action. The FDA has recently approved exenatide, a synthetic peptide of natural exendin-4 for use in patients with type 2 diabetes who have suboptimal glycemic control, despite treatment with metformin and/or sulfonylureas.\(^{(83)}\)

In a trial, 109 patients with type 2 diabetes who demonstrated inadequate glycemic control with sulfonylureas and/or metformin and had an Hba1c > 8% were randomised to receive either 0.08 µg/kg exenatide subcutaneously 2 to 3 times daily or placebo. After 28 days of treatment, there was a significant reduction in mean Hba1c compared with placebo. No significant change was observed in body weight or serum lipids. The most common adverse effect was nausea.\(^{(84)}\)
Several other studies with higher doses (5 and 10 μg/kg) have shown significant decrease in HbA1c levels. Nausea, diarrohea, vomiting, and hypoglycemia were the common adverse effects. In a trial of patients with type 2 diabetes who had failed to achieve glycemic control with maximally effective metformin doses, exenatide reduced HbA1c with no weight gain and no increased incidence of hypoglycemia. In another trial, exenatide significantly reduced HbA1c in patients with type 2 diabetes who were unable to achieve adequate glycemic control with maximal effective doses of combined metformin-sulfonylurea therapy. The improvement in glycemic control was not associated with weight gain and treatment was generally well tolerated. In all these trials, the common adverse effects related to treatment were hypoglycemia, nausea, vomiting, diarrohea, jitteriness, dizziness, and headache.

It has been observed that gradual escalation of dose of exenatide successfully reduces the proportion of subjects experiencing nausea and vomiting that limit the dose. There is no loss of glucoregulatory activity. Exenatide should be initiated at a dosage of 5 μg twice a day. The dose can be increased to 10 μg twice daily, after one month of treatment, depending on the clinical response.

Another long acting formulation of exenatide is being tried on animals so as to minimise the side effects and the difficulty of repeated injections. A single dose of exenatide-LAR (long acting release) enhanced the glucose control for 28 days in the ZDF rat model of type 2 diabetes. This suggests that tachyphylaxis is unlikely to be a feature of exenatide-LAR preparations and supports further clinical exploration.

Another analog of GLP-1 under clinical investigation is NN2211 (liraglutide). It has a 97% homology with GLP-1. It is released slowly from the injection site and has a fatty acid binding moiety leading to albumin binding. After a single injection, (the half-life of liraglutide is 11-15 h) there is a decrease in glucagon and an increase in insulin levels. A single daily dose improves the glucose profile within 24 h in type 2 diabetics. Phase 1 study with subcutaneous injections of single escalating doses of liraglutide in healthy male subjects has shown increase in secretion of insulin during an intravenous glucose tolerance test. Minor side effects reported were headache, dizziness, nausea and vomiting.

Another analog of GLP-1, CJG-1131, is composed of a D-Ala8-substituted GLP-1 molecule with a linker and a reactive moiety attached to the COOH-terminus. After injection in vivo, this molecule conjugates covalently to Lys34 of albumin and acquires the half-life of albumin. Studies on rodents have demonstrated the insulinotropic activities of CJG-113173 which currently is in phase 2 clinical trials. Twice daily administration of CJG-1131 to db/db mice significantly reduced glycemic excursion following oral and IP glucose challenge (P<0.05), but did not significantly lower body weight during the 4-week study period. CJG-1131 increased the levels of pancreatic proinsulin mRNA transcripts, percent area of islet, and number of bromodeoxyuridine-positive islet cells. CJG-1131 covalently couples with HSA (human serum albumin) after parenteral administration and liraglutide binds to albumin in a noncovalent dissociable manner. Another agent, albugon, is a fusion protein consisting of DPP-IV resistant analog of GLP-1, which is covalently bound to human albumin. Therefore, no "free" GLP-1 is associated with administration of albugon in vivo. Albugon activates the cloned GLP-1R, but with a reduced affinity relative to the potent GLP-1R agonist exendin-4. Given the intense interest in the development of long-acting agonists of GLP-1R for the treatment of type 2 diabetes, the biological properties and mechanisms of action of GLP-1–albumin derivative merit further investigation.

Inhibitors of DPP-IV

As GLP and GLP-1 are cleaved by DPP-IV, inhibition of this enzyme can also increase the levels of incretin hormones. Many studies on animals and humans have shown prolongation of GIP and GLP-1 activity and improved glycemic control with inhibitors of DPP-IV.

Many inhibitors of DPP-IV are under clinical development. Vildaglaptin (LAF237), a second-generation drug is under phase III trials. In a one-year trial of 107 metformin treated patients with type 2 diabetes, 56 received LAF237 (50 mg daily) plus metformin (mean 1.8 g daily) and 51 received metformin plus placebo. At three months, HbA1c was 0.7% lower with a decrease in fasting and postprandial glucose of 22 and 40 mg/dl, respectively, in the vildaglaptin group. After a follow-up of 1 year, HbA1c remained stable in the test group, while in the placebo group the HbA1c increased to 8.4%, and there was no effect on weight. Vildaglaptin improves β-cell function in diabetic patients by increasing secretory tone of insulin.

A novel series of β-amino amides incorporating fused heterocycles, that is, triazolopiperazines, were synthesised and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-IV) for the treatment of type 2 diabetes. (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine (1) is a potent, orally active inhibitor of DPP-IV (IC50 = 18 nM) with excellent selectivity over other proline-selective peptidases, oral bioavailability in preclinical species, and in vivo efficacy in animal models. MK-0431, the phosphate salt of this compound has been selected for development as a potential new treatment for type 2 diabetes. Many other compounds are being developed. Oral metformin also inhibits DPP IV activity in type 2 diabetic patients, suggesting that the drug may have potential for future combination therapy with incretin hormones.

Drawbacks of inhibitors of DPP-IV: There is limitation to the development of inhibitors of DPP-IV as drugs. DPP-IV enzyme exhibits catalytic activity against a broad range of peptides, for example, neuropeptide Y, endomorphin and peptide YY. Therefore, selective inhibition is required. Furthermore, DPP-IV, also known as the lymphocyte cell surface transmembrane –signaling molecule CD26, is activated by external stimuli and modulates T-cell activation, producing pleiotropic effects in experimental inflammatory and neoplastic disorders. Global genetic inactivation of CD26 in mice is associated with subtle, but detectable abnormalities in the secretion of cytokine and immunoglobulin after stimulation of mitogen. Highly selective inhibitors of DPP-IV are under clinical development.

The advantage of inhibitors of DPP-IV over agonists of GLP-1 is that they can be given orally, while the latter have to be
administered subcutaneously. However, the side effects of inhibitors of DPP-IV are not known now. In Table 1. In addition, the effect of inhibitors of DPP-IV will be less than receptor agonists of GIP-1 in type 2 diabetic patients. This is because the circulating levels of GIP-1, stimulated by meals, are reduced in such patients.

**Conclusion**

With the approval of exenatide for clinical use, there is increasing interest in the development of drugs targeting the incretins, for example, secretagogues of GLP-1 or GLP-1 receptor activators. The availability of this new group of agents may be helpful for patients in whom it has been difficult to reach the target levels with the available agents. The lesser incidence of hypoglycemia coupled with no weight gain gives this group of drugs an advantage over the drugs that are currently available. The disadvantage of frequent dosing schedule of exenatide may be overcome with the availability of longer acting agents. These drugs provide a novel and much needed expansion of the therapeutic options available and lend momentum to the continued effort to advance our understanding and treatment of this complex disease.

**References**

29. Glucagon.com [homepage on the internet]. Toronto General Hospital, Baning and Best Diabetes Centre, University of Toronto. [Accessed on 2005 Sep 28].


